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OBJECTIVES We hypothesized that the increased urinary Ca2 and Mg2 excretion and bone loss that
accompanies aldosteronism is aggravated with furosemide and is attenuated by spironolac-
tone.
BACKGROUND Furosemide, a loop diuretic, is commonly used in patients with congestive heart failure
(CHF), in which chronic, inappropriate (dietary Na) elevations in plasma aldosterone
(ALDO) and a catabolic state that includes bone wasting are expected.
METHODS In age- and gender-matched, untreated controls, four weeks of aldosterone/salt treatment
(ALDO/salt, 0.75 g/h 1% NaCl/0.4% KCl in drinking water), four weeks of ALDO/salt
 furosemide (40 mg/kg in prepared food), and four weeks of ALDO/salt  furosemide 
spironolactone (200 mg/kg/day in divided doses by twice-daily gavage), we monitored: 24-h
urinary Ca2 and Mg2 excretion; plasma-ionized [Ca2]o and [Mg2]o, K, and
parathyroid hormone (PTH); and bone mineral density (BMD) in the femur.
RESULTS The ALDO/salt increased (p  0.05) urinary Ca2 and Mg2 excretion (4,969  1,078 and
3,856 440 g/24 h, respectively) compared with controls (896 138 and 970 137 g/24
h, respectively); furosemide co-treatment further increased (p  0.05) urinary Ca2 and
Mg2 excretion (6,976  648 and 6,199  759 g/24 h, respectively), whereas spironolac-
tone co-treatment attenuated (p  0.05) these incremental losses (4,003  515 and 3,915 
972 g/24 h). Plasma [Ca2]o was reduced (p  0.05) at week 4 ALDO/salt  furosemide
and was accompanied by hypokalemia (3.4 mmol/l) that were rescued by spironolactone.
Plasma PTH was increased (p  0.05) compared with controls (30  4 vs. 11  3 pg/ml,
respectively), whereas BMD was decreased (p  0.05) with ALDO/salt and ALDO/salt 
furosemide, but not with spironolactone co-treatment.
CONCLUSIONS In aldosteronism, hypercalciuria and hypermagnesuria and accompanying decrease in plasma-
ionized [Ca2]o and [Mg2]o lead to hyperparathyroidism that accounts for bone wasting.
Furosemide exaggerates these losses, whereas its combination with spironolactone attenuates
these responses to prevent bone loss. (J Am Coll Cardiol 2005;46:142–6) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.055American College of Cardiology Foundation
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fhe origins of congestive heart failure (CHF), a clinical
yndrome with characteristic signs and symptoms, are
ooted in neurohormonal activation that includes the renin-
ngiotensin-aldosterone system, sympathetic nervous sys-
em, arginine vasopressin, and a family of natriuretic pep-
ides. Congestive heart failure is accompanied by a systemic
llness that includes bone wasting. Bone mineral density
BMD) is reduced in patients with CHF of moderate to
arked severity, in which a potent loop diuretic, furo-
emide, is commonly used for prolonged periods of time
1–5). Pathogenic mechanisms involved in the appearance
f bone wasting in CHF are under investigation.
This laboratory has focused on one aspect of the complex
eurohormonal profile seen in CHF: aldosteronism, defined
s inappropriate (relative to dietary Na intake), chronic
levation in plasma aldosterone (ALDO). A rat model of
ldosteronism is used in which uni-nephrectomized rats
eceive a 1% NaCl diet together with an infusion of ALDO
by mini-pump) to increase its plasma levels to those found
n human CHF (6). In this ALDO/salt treatment model,
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ennessee. This work was supported in part by NHLBI R01 HL73043 (Dr. Weber)
nd the NIH Medical Student Research Program T35 DK07405 (Mr. Law).s
Manuscript received November 11, 2004; revised manuscript received January 21,
005, accepted March 17, 2005.e have observed an early and persistent increase in urinary
nd fecal Ca2 and Mg2 excretion, which ultimately leads
o a reduction in BMD and bone strength (7,8). The
ong-term use of furosemide in the setting of aldosteronism
ould prove detrimental, but has not been examined.
erein, we hypothesize furosemide would augment the
ypercalciuria and hypermagnesuria seen with aldosteron-
sm and lead to a loss of bone minerals, which could be
escued by co-treatment with spironolactone, an ALDO
eceptor antagonist that reduces both urinary and fecal
osses of these divalent cations (8). Accordingly, at four
eeks of ALDO/salt we monitored: 24-h urinary Ca2 and
g2 excretion; plasma-ionized [Ca2]o and [Mg2]o
oncentrations, K and parathyroid hormone (PTH); and
MD of femur. Separate animals received ALDO/salt
ogether with furosemide in combination with spironolac-
one. Age- and gender-matched, unoperated, untreated rats
erved as controls.
ETHODS
nimal model. Male Sprague-Dawley rats (Harlan, Indi-
napolis, Indiana) were used in this study approved by the
nstitution’s Animal Care and Use Committee. There were
our groups with five rats in each group unless otherwise
pecified. Age- and gender-matched, unoperated, untreated
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July 5, 2005:142–6 Diuretics and Bone Lossats served as controls. As previously reported (7), ALDO/
alt consists of uni-nephrectomized rats receiving ALDO
0.75 g/h) by implanted mini-pump (Alzet, Cupertino,
alifornia) together with 1% NaCl/0.4% KCl in drinking
ater and standard laboratory chow (Harlan Teklad 2215
odent Diet, Madison, Wisconsin) containing 1.13%
a2. A separate group of animals received ALDO/salt
lus daily furosemide. Furosemide (40 mg/kg) was mixed
nto powdered standard chow, and water was added. The
ixture was placed in a pan and cut into small squares and
ir dried. During the 24-h collection of urine in a metabolic
age (see the following text), animals continued to receive
urosemide provided by twice-daily gavage. Another group
f rats received furosemide plus spironolactone (200 mg/kg/
ay) in divided doses by twice-daily gavage. Finally, animals
ere anesthetized and killed, and blood and femur were
arvested at four weeks of treatment.
rinary Ca2 and Mg2 excretion. On the day of the
etabolic study, food was withheld, but water with 1%
aCl was provided. Animals were gently bathed using
istilled water to remove any feces or food that could
ontaminate collected urine. Animals were then placed in a
leaned, minerally decontaminated and distilled-deionized,
ater-rinsed metabolic cage. Urine was collected over 24 h
nd kept frozen for Ca2 and Mg2 assay. After each use,
ages were manually cleaned with deionized water, all
onmetallic parts were washed with diluted hydrochloric
cid (3N), and cages were rinsed three times with deionized
ater and finally rinsed twice with distilled-deionized water
or future use as previously reported (7,8).
Urinary Ca2 and Mg2 concentrations were determined
s reported elsewhere (7,8) using an atomic absorption
pectrophotometer. Urinary Ca2 and Mg2 excretion rates
ere calculated from the product of their concentration
g/ml) by the 24-h urine volume (ml/24 h) and expressed
s g/24 h.
lasma-ionized [Ca2]o and [Mg2]o and plasma
. The concentrations of plasma-ionized [Ca2]o and
Mg2]o and plasma K were determined by the direct
on-selective electrode technique using a Nova 8 Analyzer
Nova Biomedical, Waltham, Massachusetts) and expressed
n mol/l.
arathyroid hormone. Plasma PTH was measured by the
ntact PTH immunoassay (IRMA) using a commercial kit
Nichols Institute Diagnostics, San Clemente, California).
he IRMA is a two-site immunoradiometric assay for the
easurement of the biologically intact 84-amino-acid chain
Abbreviations and Acronyms
ALDO  aldosterone
BMD  bone mineral density
CHF  congestive heart failure
DOC  deoxycorticosterone
PTH  parathyroid hormonef the PTH molecule. Blood (two ml) was collected from 5he rat heart into a chilled ethylenediaminetetraacetic acid
ube and immediately centrifuged (1,600 g) for 15 min.
lasma was then separated and kept at80 °C. For IRMA,
ach plasma sample (200 l) was added to the tube
ontaining 100 l of the 125I-PTH antibody solution and
TH antibody-coated beads and incubated for 24 h. Beads
ere then washed twice with washing solution, and each
est tube was counted with gamma counter for 1 min. A
tandard curve was generated using prepared intact PTH
tandards, and plasma PTH values were expressed as pg/ml.
MD. The BMD was determined for excised, manually
leaned femurs by peripheral dual-energy X-ray absorpti-
metry using GE Lunar PIXImus2 (GE Healthcare, Fair-
eld, Connecticut). Quality control and calibration were
arried out within 24 h of each scanning period. This
ethod has been validated for rat long bones (9). We have
reviously reported on the equivalency of this noninvasive
ssessment of tibia and femur BMD with their total
oncentrations of Ca2 and Mg2 determined by atomic
bsorption spectrophotometry (7).
tatistical analysis. Values are presented as mean  stan-
ard error of the mean (SEM). Analysis was on square
oot-transformed data to minimize variability. Significant
ifferences between individual means were determined us-
ng the Bonferroni multiple comparisons test. Significance
as assigned as p  0.05.
ESULTS
rinary Ca2 and Mg2 excretion. The Ca2 and Mg2
xcretion in unoperated, untreated controls were 896  138
nd 970  137 g/24 h, respectively (Table 1). Four weeks
f ALDO/salt was accompanied by hypercalciuria and
ypermagnesuria. In co-treating rats receiving ALDO/salt
ith furosemide, the 24-h urinary Ca2 and Mg2 excre-
ion increased further. The addition of spironolactone to the
LDO/salt  furosemide regimen significantly reduced
his level of divalent cation loss.
lasma-ionized [Ca2]o and [Mg2]o. Plasma [Ca2]o
n unoperated, untreated controls was 0.89  0.02 mmol/l.
t four weeks of ALDO/salt and with furosemide co-
reatment, [Ca2]o was reduced (0.83  0.03 and 0.77 
.09 mmol/l, respectively, p  0.05). A decrease in plasma-
onized [Ca2]o was not seen with the ALDO/salt 
urosemide  spironolactone regimen (0.87  0.05
mol/l).
Plasma-ionized [Mg2]o in untreated controls was 0.34
0.01 mmol/l. At four weeks of ALDO/salt and with
LDO/salt  furosemide, plasma [Mg2]o was reduced
ut did not reach statistical significance (0.31  0.02 and
.30  0.01 mmol/l, respectively). Plasma [Mg2]o was
.32  0.02 mmol/l in the group receiving ALDO/salt 
urosemide  spironolactone.
lasma K. Plasma K levels in unoperated untreated
ontrols was 4.3  0.2 mmol/l and ranged between 3.4 and
.1 mmol/l. At four weeks of ALDO/salt plus 1% NaCl and
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Diuretics and Bone Loss July 5, 2005:142–6.4% KCl in drinking water, plasma K was 4.0  0.03
mol/l. In rats receiving ALDO/salt  furosemide, plasma
 decreased (p  0.05) to 3.0  0.1 mmol/l, whereas
hose on the regimen of ALDO/salt  furosemide 
pironolactone, plasma K was 4.7  0.02 mmol/l.
A value below 3.4 mmol/l was defined as hypokalemia.
ll five rats receiving ALDO/salt  furosemide developed
ypokalemia, with two of five rats having a plasma K level
elow 3.0 mmol/l. None of the rats receiving ALDO/salt
urosemide  spironolactone developed hypokalemia, and
n none of these rats did plasma K exceed 5.1 mmol/l.
arathyroid hormone. Plasma levels of PTH in unoper-
ted and untreated controls was 11  3 pg/ml. At four
eeks of ALDO/salt, circulating levels of PTH had in-
reased (p  0.05) to 30  4 pg/ml.
MD. The BMD for the femurs of 12-week-old, male-
atched, untreated controls was 0.169  0.002 g/cm2. In
eeping with the marked and sustained hypercalciuria and
ypermagnesuria seen with ALDO/salt, BMD was signif-
cantly (p  0.05) reduced at four weeks of ALDO/salt
lone and with ALDO/salt  furosemide (0.153  0.006
nd 0.151  0.006 g/cm2, respectively). Co-treatment with
pironolactone, which attenuated the excretion of Ca2 and
g2 seen with ALDO/salt plus loop diuretic, prevented
his decrease in BMD (0.165  0.003 g/cm2).
ISCUSSION
ur study shows the importance of well-known properties
f furosemide and spironolactone as they apply to aldoste-
onism. It further addresses the impact of urinary Ca2 and
g2 excretion on bone health in this setting. There were
everal major findings. First, the marked hypercalciuria and
ypermagnesuria that accompanies chronic ALDO/salt is
xaggerated by furosemide (7,8). Short-term studies in rats
ave previously identified the hypercalciuria that accompa-
ies mineralocorticoid excess and that was induced by either
LDO or deoxycorticosterone (DOC) treatment, together
ith inappropriate dietary NaCl (10–13). In humans,
hort-term treatment with a mineralocorticoid (inappropri-
te for dietary Na) likewise leads to hypercalciuria (14,15).
he elevated baseline urinary Ca2 excretion seen in pa-
ients with primary aldosteronism is augmented further by
ietary Na loading (15) and can be normalized by surgical
emoval of diseased adrenal tissue or spironolactone treat-
able 1. Urinary Ca2 and Mg2 Excretion at Week 4
reatment
Ca2 (g/24 h) Mg2 (g/24 h)
895  138 (5) 970  137 (5)
4,969  1,078 (4)* 3,856  440 (5)*
F 6,976  648 (4)*† 6,199  759 (5)*†
FS 4,003  515 (4)*‡ 3,915  972 (5)‡
ean  SEM (n). *p  0.05 vs. C; †p  0.05 vs. A; ‡p  0.05 vs. AF.
A  4 wks ALDO/salt; AF  4 wks ALDO/salt  furosemide; AFS  4 wks
LDO/salt  furosemidespironolactone; C  untreated controls. Other abbrevi-
tions as in text.ent (16). Urinary Mg2 excretion is also increased in Aatients with primary aldosteronism and is abrogated by
ither spironolactone or adrenal surgery (17).
The hypercalciuria associated with aldosteronism is
hought to be related to an expansion of extravascular fluid
olume with resultant reductions in proximal tubular Na
nd Ca2 resorption. This leads to their increased delivery
o distal segments of the nephron, where the mineralocor-
icoid promotes Na resorption without affecting Ca2 that
esults in hypercalciuria. A subsequent decrease in plasma
Ca2]o stimulates the secretion of PTH (18). The miner-
locorticoid hormone itself and the accompanying elevation
n arterial pressure have each been eliminated as causative of
eightened Ca2 excretion (10–12,15), as have accompa-
ying polydipsia and metabolic alkalosis secondary to renal
cidification (13,19).
As expected, plasma-ionized [Ca2]o decreased with
LDO/salt and was markedly reduced with ALDO/salt 
urosemide; this was rescued by spironolactone co-
reatment. A decrease in [Mg2]o was also seen with
LDO/salt and ALDO/salt  furosemide. Parathyroid
ormone is released in response to these iterations in plasma
Ca2]o and [Mg2]o (8,18). Elevations in plasma PTH
nd PTH-driven renal formation of 1,25(OH)2D3 respec-
ively promote Ca2 resorption from bone and Ca2 ab-
orption from the gastrointestinal tract. Serum levels of
TH and duodenal absorption of Ca2 are each increased
n rats treated with DOC/salt (13,20,21). Secondary hyper-
arathyroidism has been reported in patients with primary
ldosteronism (22), in which reduced [Ca2]o and in-
reased PTH concentrations have been normalized by
pironolactone or adrenal surgery (16,22).
Furosemide has well-known nephrogenic effects that
romote the urinary excretion of Ca2and Mg2. Herein,
e found furosemide to exaggerate urinary Ca2 excretion
hat accompanies ALDO/salt. Of additional importance
nd despite a diet containing 0.4% supplemental KCl,
hich prevents hypokalemia in ALDO/salt, hypokalemia
eveloped in many of the rats with aldosteronism that were
eceiving furosemide. Spironolactone co-treatment pre-
ented hypokalemia. Hypokalemia and hypomagnesemia,
ogether with reduced concentrations of these cations in
keletal muscle, accompany chronic diuretic therapy in
atients with cardiovascular disease and can be rescued by
pironolactone co-treatment (23–26). Additionally, it is
ow recognized that furosemide inhibits renal tubular 11-
eta-hydroxysteroid dehyrogenase-2, a guardian enzyme
hat preserves the specificity of the promiscuous ALDO
eceptor for mineralocorticoids. In so doing, furosemide
ay permit more plentiful glucocorticoids to act as a
ineralocorticoid and further enhance urinary K excretion
27,28). Potassium-sparing diuretics, such as spironolac-
one, are associated with a reduced risk of death and
ospitalization for progressive heart failure and all-cause
ortality in patients with heart failure (29).
The loss of BMD during furosemide treatment in rats withLDO/salt is our second major finding. This occurs as a
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July 5, 2005:142–6 Diuretics and Bone Lossompensatory response to elevations in circulating PTH
voked to preserve extracellular Ca2 homeostasis. The long-
erm usage of furosemide may have deleterious effects on Ca2
nd Mg2 balance and lead to secondary hyperparathyroidism
espite increased gastrointestinal Ca2 absorption (30–33). In
ur study, in which hypercalciuria and hypermagnesuria appear
n response to ALDO/salt, additional losses of Ca2 and
g2 induced by furosemide lead to a rapid decline in BMD.
thers have inferred that bone loss occurs with rat models of
hronic mineralocorticoid excess. For example, urinary hy-
roxyproline, an indirect measure of bone resorption, is in-
reased in this setting (21,34,35).
Reductions in BMD and elevations in plasma PTH are
ound in patients with advanced heart failure awaiting cardiac
ransplantation as well as in patients with moderately severe
HF (1–5,36–39). The chronic use of furosemide in these
ymptomatic patients, in whom secondary aldosteronism is
xpected, may be contributory to the observed osteopenia and
econdary hyperparathyroidism. The importance of preserving
one homeostasis and the prevention of bone loss with its
ncreased potential for fracture is clear, particularly among
lderly patients. Thiazide diuretics are known to reduce bone
oss and the risk of bone fracture in elderly men and women
nd in postmenopausal women in general (40–44). The
election of a diuretic in any given patient should take into
ccount their state of Ca2 balance. For example, in elderly
atients, a thiazide diuretic or ALDO receptor antagonist
eems preferable to a loop diuretic. A thiazide will rescue
rinary Ca2 but not urinary Mg2 losses that accompany
ldosteronism, whereas the combination of hydrochlorothia-
ide and spironolactone normalizes urinary Ca2 and Mg2
xcretion in this setting (45). Unless the reduction in plasma-
onized [Ca2]o and [Mg2]o that accompany hypercalciuria
nd hypermagnesuria are each rescued, an elevation in plasma
TH with bone resorption can be expected (46–48). Among
ursing home residents, the daily dose of furosemide is an
mportant predictor of hyperparathyroidism (49).
Third, we found that spironolactone co-treatment serves
o prevent the reduction in BMD seen at four weeks of
LDO/salt  furosemide. Spironolactone is protective
gainst bone loss by reducing both urinary and fecal Ca2
nd Mg2 excretion (8). Albeit a salutary response in this
at model, it remains to be seen whether long-term spirono-
actone use in humans would prevent osteopenia and even
steoporosis in heart failure patients receiving furosemide.
dditional measures, such as dietary Ca2 supplements,
ould theoretically prevent bone loss by attenuating PTH
ecretion. In rats with chronic mineralocorticoid/salt excess,
owever, a Ca2-supplemented diet alone did not lower
lasma PTH (50). A diet with combined Ca2 and Mg2
upplements would likely provide a more complete suppres-
ion of PTH release as noted earlier, particularly when
urosemide is used in the setting of aldosteronism.
Although it was introduced into clinical practice more
han 30 years ago, the safety of furosemide in the long-term
anagement of CHF has never been systematically evalu-ted (51). This notwithstanding, the combination of a small
ose of spironolactone, together with furosemide and an
ngiotensin-converting enzyme inhibitor, has proven effec-
ive in the overall management of CHF, including the
eduction in risk for sudden cardiac death (52). The efficacy
f spironolactone as co-treatment with furosemide in CHF
ay include its ability to rescue the renal and gastrointes-
inal losses of Ca2 and Mg2 that occur with aldosteron-
sm and hence better preserve the extracellular and intracel-
ular homeostasis of these divalent cations (8). In so doing,
pironolactone could prevent the hyperparathyroidism and
TH-mediated Ca2 loading of myocardium and the ac-
ompanying increased propensity for arrhythmias.
tudy limitations. Our study has several limitations. First,
e did not monitor daily food consumption in each animal
nd therefore cannot account for the exact dose of admin-
stered furosemide. In preparing food supplemented with
urosemide, we selected a dose previously reported as
ffective in rodents (31,53). Second, we monitored plasma
TH only in the ALDO/salt treatment group, in which it
as elevated, as is the case in rats receiving DOC/salt
21,34) and in patients with primary aldosteronism (16,22).
e therefore cannot address the appearance of hyperpara-
hyroidism in furosemide-treated animals with aldosteron-
sm. Serum PTH and PTH activity (i.e., urinary cyclic
denosine monophosphate) are each increased in normal
ats, human infants, and adult volunteers receiving furo-
emide (30–32,54,55). A calcimimetic agent, which acts as
n agonist at the calcium-sensing receptor in parathyroid
lands, serves to prevent hyperparathyroidism in
urosemide-treated rats (55). Finally, we cannot address the
otential of spironolactone to prevent the occurrence of
yperparathyroidism in rats with aldosteronism receiving
urosemide. However, spironolactone prevents a decrease in
lasma-ionized [Ca2]o and [Mg2]o (8). It therefore
ould be expected to be effective in this regard.
eprint requests and correspondence: Dr. Karl T. Weber,
ivision of Cardiovascular Diseases, University of Tennessee
ealth Science Center, 920 Madison Avenue, Suite 300, Mem-
his, Tennessee 38163. E-mail: KTWeber@utmem.edu.
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